Selumetinib: Instructions and Details

1. Overview of drugs

Selumetinib (Selumetinib) is an inhibitor that specifically targets MEK (mitogen kinase) and has been approved for the treatment of 2 patients aged 2 and above Pediatric patients with pan>1 type neurofibroma (NF1) and symptomatic, inoperable plexiform neurofibroma (PN).

2. Drug ingredients

Each selumetinib capsule contains 10mg or 25mg of the active ingredient selumetinib, and is supplemented with an appropriate amount of pharmaceutical excipients.

3. Indications

This drug is primarily used to treat NF1 patients who meet certain conditions, particularly children with PN symptoms that cannot be treated with surgery.

4. Pharmacological mechanism

Selumetinib precisely inhibits the activity ofMEKkinase, thereby blocking the conduction of the extramitochondrial signal-regulated kinase (MAPK) signaling pathway. This pathway plays a key role in the development of neurofibromas. By inhibiting this pathway, selumetinib can slow down the growth of NF cells and promote apoptosis, thereby achieving therapeutic purposes.

5. Administration and dosage

The recommended dosage is25mg/m² (body surface area) , taken orally twice daily on an empty stomach. To ensure optimal absorption of the medication, it is recommended to avoid eating 2 hours before or 1 hour after taking the medication.

6. Taboos

This drug should not be used in patients who are allergic to selumetinib or any of its components.

7. Adverse reactions

Common adverse reactions include fever, vomiting, diarrhea, rash, drowsiness and loss of appetite. Serious adverse reactions may include periretinal edema, eye disease, elevated creatine kinase, and interstitial lung disease. During use, patients should be closely monitored for adverse reactions and appropriate treatment measures should be taken as necessary.

8. Special precautions

1.Before using selumetinib, patients should inform their doctor of all medications they are taking to avoid potential drug interactions.

2.Patients should avoid prolonged exposure to the sun during medication and take appropriate sun protection measures.

3.Pregnant and breastfeeding women should consult a doctor before use to evaluate potential risks and benefits.

4.Because this drug may cause eye problems, such as edema around the retina, it is recommended that patients receive regular eye examinations while taking the drug.

5.If serious adverse reactions or allergic reactions occur, patients should stop taking the medication immediately and seek medical help.

9. Storage suggestions

Store selumetinib in a dry, cool place, out of direct sunlight, and out of the reach of children.

10. Validity period

This medicine is valid for 24 months from the date of manufacture. Please use it within the validity period.

101. Market and price information

The original drug of selumetinib has been launched in China and is covered by medical insurance. Patients can purchase it directly in China at a price of about more than 20,000 yuan. For specific prices and medical insurance reimbursement ratios, please consult your local hospital pharmacy. In addition, the world's first generic version of selumetinib has also been released, produced by Lucius Pharmaceuticals in Laos. The price of this generic drug is much lower than that of the original drug, about more than 2,000 yuan. At the same time, it maintains similar ingredients to the original drug, providing patients with a more economical treatment option.

The above information is for reference only. Patients should read the instructions carefully and follow the doctor's instructions before using selumetinib. If you have any questions or need further help, ask your doctor or pharmacist.